News (85)

Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML GL
Novartis: positive data for malaria treatment CF
Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria GL
Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash GL
Novartis Scemblix shows superior major molecular response rates vs. standard of care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid leukemia AQ
Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard‐of‐care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid leukemia GL
Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy AQ
Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G) GL
Transcript : Novartis AG - Special Call
Novartis investigational atrasentan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN) GL
Transcript : Novartis AG - Shareholder/Analyst Call
Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN) GL
Novartis remibrutinib Phase III trials met their primary endpoints and showed rapid symptom control in chronic spontaneous urticaria GL
Transcript : Novartis AG Presents at 2023 American Society of Clinical Oncology Annual Meeting, Jun-04-2023 07:00 PM
Novartis Kisqali® significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups GL
Novartis to present new data across oncology portfolio including Kisqali Phase III NATALEE trial in early breast cancer at ASCO GL
Novartis Kisqali® Phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in broad population of patients with early breast cancer GL
Novartis PluvictoTM shows statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with PSMA–positive metastatic castration-resistant prostate cancer GL
Novartis investigational oral monotherapy iptacopan demonstrates clinically meaningful superiority over anti-C5 treatment in Phase III APPLY-PNH study GL
Transcript : Novartis AG - Special Call
AXCELLA HEALTH INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders (form 8-K) AQ
Axcella Health Inc. Announces Management Changes CI
NOVARTIS : Pursuing a leaner organisational structure Alphavalue
Transcript : Novartis AG - Special Call
Novartis to save at least $1 billion by 2024 thanks to simplified structure RE
Novartis AG Announces Executive Changes CI
Dicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021 BU
Transcript : Dicerna Pharmaceuticals, Inc., Q3 2021 Earnings Call, Nov 09, 2021
 Dicerna Presents PHYOX™2 and Primary Hyperoxaluria Healthcare Utilization Data at American Society of Nephrology (ASN) Kidney Week 2021 BU
Dicerna Pharmaceuticals : Announces Results for PHYOX4, Single-Dose Study of Nedosiran in Primary Hyperoxaluria Type 3 (PH3) AQ
Dicerna Pharmaceuticals : Announces Results for PHYOX™4, Single-Dose Study of Nedosiran in Primary Hyperoxaluria Type 3 (PH3) BU
Dicerna Pharmaceuticals : Initiates Phase 1 Clinical Trial of DCR-AUD, a Novel Investigational GalXC RNAi Therapeutic Candidate for the Treatment of Alcohol Use Disorder AQ
Dicerna Pharmaceuticals : Initiates Phase 1 Clinical Trial of DCR-AUD, a Novel Investigational GalXC™ RNAi Therapeutic Candidate for the Treatment of Alcohol Use Disorder BU
Transcript : Dicerna Pharmaceuticals, Inc., Q2 2021 Earnings Call, Aug 09, 2021
Transcript : Dicerna Pharmaceuticals, Inc. - Special Call
Dicerna Pharmaceuticals : Reports Positive Top-Line Results From PHYOX™2 Pivotal Clinical Trial of Nedosiran for the Treatment of Primary Hyperoxaluria BU
Dicerna Pharmaceuticals : Announces Interim Results From Phase 1 Trial of Belcesiran for Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease BU
Dicerna Pharmaceuticals : Initiates Patient Dosing in ESTRELLA Phase 2 Clinical Trial of Belcesiran for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease BU
Dicerna Pharmaceuticals : Announces Dosing Completion in Nedosiran PHYOX4 Clinical Trial for Treatment of Primary Hyperoxaluria Type 3 AQ
Dicerna Pharmaceuticals : Announces Dosing Completion in Nedosiran PHYOX™4 Clinical Trial for Treatment of Primary Hyperoxaluria Type 3 BU
AXCELLA HEALTH INC. : Submission of Matters to a Vote of Security Holders (form 8-K) AQ
Transcript : Dicerna Pharmaceuticals, Inc., Q1 2021 Earnings Call, May 06, 2021
Transcript : Dicerna Pharmaceuticals, Inc. - Special Call
Dicerna Pharmaceuticals : Announces Roche’s Initiation of GalXC™ RNAi Candidate RG6346 in Phase 2 Combination Trial for Treatment of Chronic Hepatitis B Virus Infection BU
Transcript : Dicerna Pharmaceuticals, Inc., 2020 Earnings Call, Feb 25, 2021
123NextSee all

Companies (1)

MARTIN BURN LIMITED 3 M $
Logo Martin Burn Limited

Martin Burn Limited is an India-based real estate development company. The Company is engaged with civic authorities and local governments to develop public spaces like Eden Gardens Club House, and S.S. Hogg Market-Phase II. The Company has developed the ...


Insiders

Picture Shreeram Aradhye
Shreeram Aradhye

Shreeram Aradhye is currently the Director at Valo Health LLC and the Chief Medical Officer & President-Development at Novartis AG.
Previously, he worked as the Chief Medical Officer & Executive Vice President at Dicerna Pharmaceuticals, Inc. and as the Chief Medical Officer at Novartis Pharmaceuticals Corp.
He also served as an Independent Director at Axcella Health, Inc. and as the Head-Global Clinical Development & Medical Affairs at Sandoz International GmbH.
Additionally, he was an Assistant Professor at the University of Pennsylvania.
Aradhye completed his undergraduate degree at the All India Institute of Medical Sciences.



Picture Shreeram Singh
Shreeram Singh

Shreeram Singh worked as an Independent Director at Mid India Industries Ltd.
from 2002 to 2014.


Picture Shreeram G. Garde
Shreeram G. Garde

Shreeram G.
Garde
has a career history that includes a current job as the Chief Financial Officer & Vice President at Jayabharat Credit Ltd.


Picture Shreeram Iyer
Shreeram Iyer

Shreeram Iyer is associated with Prisma Technologies Pte Ltd.
and Prisma AI Corp.
Pte Ltd.
He currently holds the position of Chief Executive Officer at Prisma Technologies Pte Ltd.
and Chairman & Group Chief Executive Officer at Prisma AI Corp.
Pte Ltd.


Picture Arun Ramchandra Aradhye
Arun Ramchandra Aradhye

Arun Ramchandra Aradhye has held various director positions in multiple companies, including Menon United Pvt Ltd, Flyga Auto Pvt Ltd, Menon Signature Pvt Ltd, and Flyga Resorts Pvt Ltd.
He is currently the Chief Financial Officer & Executive Director at Menon Bearings Ltd.






Picture Shreeram Hanumanbux Taparia
Shreeram Hanumanbux Taparia

Shreeram Hanumanbux Taparia was a Chairman at Permanent Magnets Ltd.
He was also a Director at Venu Plantations Ltd.
In addition, he held the position of Independent Non-Executive Director at Supreme Industries Ltd.
from 2011 to 2014.


Picture Shreeram N. Agharkar
Shreeram N. Agharkar

Shreeram N.
Agharkar
worked as an Executive Director of Pharmaceutics R&D at Bristol Myers Squibb Co. He was also a Vice President & Deputy Head-Global Chemistry at Sanofi.
In addition, he served as a Director at Relmada Therapeutics, Inc. and was an Independent Director there from 2014 to 2016.
He was a Member of the American Association of Pharmaceutical Scientists, Drug Information Association, and Parenteral Drug Association.
Dr. Agharkar holds a graduate degree from The Trustees of Columbia University in The City of New York, a doctorate from the University of Kansas, and an undergraduate degree from the University of Mumbai.


Picture Meher Shreeram Pophali
Meher Shreeram Pophali

Meher Shreeram Pophali is currently working as the Chief Technology Officer & Director at Micropro Software Solutions Ltd.
He previously worked as a Customer Engineer at HCL Infosystems Ltd.
from 1990 to 1995.
Mr. Pophali graduated from Nagpur University in 1989.



Picture Shreeram R. Mohite
Shreeram R. Mohite

Shreeram R.
Mohite
has worked as the CFO & Investor Relations Contact at Borax Morarji Ltd.
since 2015.




Picture Jayant V. Aradhye
Jayant V. Aradhye

Jayant V.
Aradhye
served as a Non-Independent Non-Executive Director at Precision Camshafts Ltd.
from 1992 to 2018.
He obtained his undergraduate degrees from the University of Pune and Dr. Babasaheb Ambedkar Marathwada University.


No results for this search